Fundz

Who to call at Atavistik Bio, and when

Fundz watches for the moments Atavistik Bio starts buying, and tells you who to reach.

  • An alert the day Atavistik Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Atavistik Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Atavistik Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

LaunchAtavistik Bio Unveils Promising Preclinical Data for ATV-1601, a Small Molecule Inhibitor Targeting AKT1 E17K Mutations

Oct 23, 2024
CambridgeBiotechnologySoftwareHealth CareScience And Engineering

Product Description

Atavistik Bio presented preclinical data on ATV-1601, a selective allosteric small molecule inhibitor for AKT1 E17K-driven cancers at the EORTC-NCI-AACR Symposium. The data highlights ATV-1601's enhanced efficacy and improved tolerability compared to existing pan-AKT inhibitors, with plans to commence human trials in early 2025.

Company Information

Company

Atavistik Bio

Location

Cambridge, Massachusetts, United States

About

Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Atavistik Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Bryan hidden

hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Atavistik Bio's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

Atavistik Bio shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.